LBA2 * Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to Dabrafenib or Trametinib
Noeparast, A., Verschelden, G., Umelo, I., de Brakeleer, S., Decoste, L., Teugels, E., de Greve, J.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv098.2
Date:
March, 2015
File:
PDF, 28 KB
english, 2015